BRAF and melanoma: In a long-term KEYNOTE-006 trial follow up, BRAF-mutated melanoma patients who were not treated with a prior BRAFi lad longer PSF on pembrolizumab treatment (7.0 months) than those who were treated initially witb RAFi (2.8 months).